← Back to Search

Cannabinoid

Cannabis Oil for Parkinson's Disease (MDC-CAN-PD Trial)

Phase 2
Waitlist Available
Led By Susan Fox, MD, PhD
Research Sponsored by University Health Network, Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline (visit 1) to follow-up phone call (1 week after visit 5); total 35 days
Awards & highlights

MDC-CAN-PD Trial Summary

This trial is testing whether cannabis oil is a safe and tolerable treatment for pain in Parkinson's disease patients. The study will also assess whether the oil affects pain, sleep, dystonia (a movement disorder), and motor symptoms.

MDC-CAN-PD Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline (visit 1) to follow-up phone call (1 week after visit 5); total 35 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline (visit 1) to follow-up phone call (1 week after visit 5); total 35 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Maximum tolerated dose (MTD) in each individual
Treatment-emergent adverse events (safety)
Secondary outcome measures
Collect the King's Parkinson Disease Pain scale (KPPS) scores in the intervention group, adjusted for baseline scores.
Other outcome measures
Changes in The Epworth Sleepiness Scale (ESS) (adjusted for baseline)
Changes in the Clinical global Impression of pain severity and improvement
Changes in the MDS-UPDRS part III (adjusted for baseline scores)
+2 more

MDC-CAN-PD Trial Design

3Treatment groups
Experimental Treatment
Group I: CanniMed® Oil 1:20 formulationExperimental Treatment1 Intervention
∆9-THC: 1.0 mg/mL; CBD: 20.0 mg/mL
Group II: CanniMed® Oil 18:0 formulationExperimental Treatment1 Intervention
∆9-THC: 18.3 mg/mL; CBD: 0.2 mg/mL
Group III: CanniMed® Oil 10:10 formulationExperimental Treatment1 Intervention
∆9-THC: 9.8 mg/mL; CBD: 9.9 mg/mL

Find a Location

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor
1,472 Previous Clinical Trials
484,978 Total Patients Enrolled
Parkinson Society CanadaOTHER
3 Previous Clinical Trials
140 Total Patients Enrolled
Susan Fox, MD, PhDPrincipal InvestigatorUHN - Toronto Western Hospital - 399 Bathurst Street, McLaughlin pavilion, 7th Floor Toronto, ON, M5T 2S8 - Canada

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Journal of Pharmacology and Experimental TherapeuticsJournal
Effects of Exogenous and Endogenous Cannabinoids on Gabaergic Neurotransmission Between the Caudate-putamen and the Globus Pallidus in the Mouse
Engler, Birgit, Ilka Freiman, Michal Urbanski, and Bela Szabo. 2005. “Effects of Exogenous and Endogenous Cannabinoids on Gabaergic Neurotransmission Between the Caudate-putamen and the Globus Pallidus in the Mouse”. Journal of Pharmacology and Experimental Therapeutics. American Society for Pharmacology & Experimental Therapeutics (ASPET). doi:10.1124/jpet.105.092718.
Molecular NeurodegenerationJournal
Promising Cannabinoid-based Therapies for Parkinson’s Disease: Motor Symptoms to Neuroprotection
More, Sandeep Vasant, and Dong-Kug Choi. 2015. “Promising Cannabinoid-based Therapies for Parkinson’s Disease: Motor Symptoms to Neuroprotection”. Molecular Neurodegeneration. Springer Science and Business Media LLC. doi:10.1186/s13024-015-0012-0.
Movement DisordersJournal
Chronic Pain in Parkinson's Disease: The Cross-sectional French Dopamip Survey
Nègre-Pagès, Laurence, Wafa Regragui, Didier Bouhassira, Héléne Grandjean, Olivier Rascol, and on behalf of the DoPaMiP Study Group (Investigators listed at end of report). 2008. “Chronic Pain in Parkinson's Disease: The Cross-sectional French Dopamip Survey”. Movement Disorders. Wiley. doi:10.1002/mds.22142.
Journal of Neuroimmune PharmacologyJournal
Cannabinoids for the Treatment of Chronic Non-cancer Pain: An Updated Systematic Review of Randomized Controlled Trials
Lynch, M. E., and Mark A. Ware. 2015. “Cannabinoids for the Treatment of Chronic Non-cancer Pain: An Updated Systematic Review of Randomized Controlled Trials”. Journal of Neuroimmune Pharmacology. Springer Science and Business Media LLC. doi:10.1007/s11481-015-9600-6.
All > Parkinson
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top